NASDAQ:PRAX Praxis Precision Medicines - PRAX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.90 +0.08 (+9.76%) (As of 03/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.80▼$0.9250-Day Range$0.82▼$4.9852-Week Range$0.80▼$13.33Volume1.19 million shsAverage Volume2.18 million shsMarket Capitalization$47.15 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Praxis Precision Medicines MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside1,066.7% Upside$10.50 Price TargetShort InterestBearish10.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingAcquiring Shares$72,100 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.60) to ($2.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector557th out of 995 stocksPharmaceutical Preparations Industry264th out of 482 stocks 3.2 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Praxis Precision Medicines has a forecasted upside of 1,066.7% from its current price of $0.90.Amount of Analyst CoveragePraxis Precision Medicines has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.65% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 37.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 3.2 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Praxis Precision Medicines this week, compared to 1 article on an average week.Search InterestOnly 35 people have searched for PRAX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows4 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $72,100.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.50% of the stock of Praxis Precision Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.31% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($2.60) to ($2.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Praxis Precision Medicines (NASDAQ:PRAX) StockPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Stock News HeadlinesMarch 6, 2023 | msn.comWilliam Blair Downgrades Praxis Precision Medicines (PRAX)March 3, 2023 | marketwatch.comPraxis Precision Medicines' Phase 2 Ulixacaltamide Primary Endpoint Misses Statistical SignificanceMarch 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 3, 2023 | msn.comPraxis crashes 42% after mid-stage data for movement disorder candidateMarch 3, 2023 | marketwatch.comPraxis Precision Medicines Shares Hit 52-Week Low After Ulixacaltamide Primary Endpoint Misses Statistical SignificanceFebruary 17, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Alkermes (ALKS)February 7, 2023 | finance.yahoo.comPraxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsJanuary 26, 2023 | seekingalpha.comPRAX Praxis Precision Medicines, Inc.March 28, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. December 14, 2022 | msn.comPraxis Precision Medicines and UCB collaborate for epilepsy researchNovember 28, 2022 | finance.yahoo.comPraxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual MeetingNovember 28, 2022 | finance.yahoo.comPraxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic EncephalopathiesNovember 9, 2022 | finance.yahoo.comPraxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | finance.yahoo.comPositive week for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional investors who lost 89% over the past yearSeptember 26, 2022 | finance.yahoo.comPraxis Precision Medicines (NASDAQ:PRAX) Will Have To Spend Its Cash WiselySeptember 23, 2022 | nasdaq.comWhy Invitae Corporation Sank as Much as 25.5% This WeekSeptember 21, 2022 | finance.yahoo.comPraxis Precision Medicines to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 7, 2022 | finance.yahoo.comPraxis Precision Outlines Upcoming Plans For Pediatric Epilepsy ProgramsSeptember 7, 2022 | finance.yahoo.comPraxis Precision Medicines to Present at H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022 | marketwatch.comPraxis Precision Medicines to Start PRAX-222 Study After FDA ClearanceSeptember 7, 2022 | finance.yahoo.comPraxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy ProgramsAugust 13, 2022 | seekingalpha.comPraxis Precision Medicines (PRAX) Investor Presentation - SlideshowAugust 9, 2022 | msn.comPrecision medicine can remodel healthcare industry - David BuntonAugust 8, 2022 | finance.yahoo.comPraxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsAugust 3, 2022 | finance.yahoo.comPraxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare ConferenceAugust 2, 2022 | nasdaq.comCan Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?July 21, 2022 | finance.yahoo.com60+ Key Companies Actively Working in the Encephalopathy Pipeline Segment | DelveInsightSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Company Calendar Last Earnings2/07/2023Today3/27/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees139Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$18.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,144.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-167.49% Return on Assets-127.41% Debt Debt-to-Equity RatioN/A Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.52Miscellaneous Outstanding Shares52,390,000Free Float46,892,000Market Cap$44.21 million OptionableNot Optionable Beta3.24 Key ExecutivesMr. Marcio Souza M.B.A. (Age 42)Pres, CEO & Director Comp: $1.24MMs. Nicole Sweeny (Age 47)Chief Commercial Officer Comp: $646.44kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerMr. Timothy Edwin Kelly (Age 49)CFO & Treasurer Lauren MastrocolaVP of Fin. & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corp. CommunicationsMr. Alex Nemiroff J.D. (Age 43)Gen. Counsel & Sec. Ms. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 47)Chief Regulatory & Quality Officer More ExecutivesKey CompetitorsGalectoNASDAQ:GLTOAtrecaNASDAQ:BCELNRx PharmaceuticalsNASDAQ:NRXPHepion PharmaceuticalsNASDAQ:HEPAHCW BiologicsNASDAQ:HCWBView All CompetitorsInsiders & InstitutionsDean J MitchellBought 50,000 shares on 3/24/2023Total: $42,000.00 ($0.84/share)Marcio SouzaBought 35,000 shares on 3/23/2023Total: $30,100.00 ($0.86/share)Voya Investment Management LLCBought 18,069 shares on 2/28/2023Ownership: 0.034%Alliancebernstein L.P.Bought 17,100 shares on 2/16/2023Ownership: 0.154%Susquehanna Fundamental Investments LLCSold 10,759 shares on 2/15/2023Ownership: 0.119%View All Insider TransactionsView All Institutional Transactions PRAX Stock - Frequently Asked Questions Should I buy or sell Praxis Precision Medicines stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAX, but not buy additional shares or sell existing shares. View PRAX analyst ratings or view top-rated stocks. What is Praxis Precision Medicines' stock price forecast for 2023? 5 brokerages have issued 12-month price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $4.00 to $18.00. On average, they anticipate the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price. View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts. How have PRAX shares performed in 2023? Praxis Precision Medicines' stock was trading at $2.38 at the start of the year. Since then, PRAX stock has decreased by 64.5% and is now trading at $0.8438. View the best growth stocks for 2023 here. Are investors shorting Praxis Precision Medicines? Praxis Precision Medicines saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,450,000 shares, an increase of 37.8% from the February 28th total of 3,230,000 shares. Based on an average daily volume of 1,970,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 10.7% of the company's shares are sold short. View Praxis Precision Medicines' Short Interest. When is Praxis Precision Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our PRAX earnings forecast. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings data on Tuesday, February, 7th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.14. When did Praxis Precision Medicines IPO? (PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager. What is Praxis Precision Medicines' stock symbol? Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX." Who are Praxis Precision Medicines' major shareholders? Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (5.45%), Verition Fund Management LLC (3.19%), EcoR1 Capital LLC (3.03%), Bank of America Corp DE (2.89%), Vida Ventures Advisors LLC (3.12%) and Geode Capital Management LLC (1.32%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Praxis Precision Medicines' stock price today? One share of PRAX stock can currently be purchased for approximately $0.84. How much money does Praxis Precision Medicines make? Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $44.21 million. The company earns $-214,030,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. How many employees does Praxis Precision Medicines have? The company employs 139 workers across the globe. How can I contact Praxis Precision Medicines? Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com. This page (NASDAQ:PRAX) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.